Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial
October 7, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, today announced the successful enrollment of the first five-patient cohort in its proof-of-concept clinical trial. The trial is evaluating the company’s drug candidate, BSG005, as a rescue therapy for patients who have failed previous standard-of-care antifungal treatments due to either lack of efficacy or safety or patients with mild to moderate kidney impairment.“We are thrilled to have filled the first cohort,” said Tine Olesen, CEO of Biosergen.